Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”) stated today that it has expanded its previously announced licensing of IMT504, unique proprietary immunotherapy, and adjuvant, to cover the development of a next-generation COVID-19 vaccine. The vaccine will first be developed for the renal failure patient group by the company.
This new License, which uses IMT504 as an adjuvant on top of a proprietary protein vaccine, adds a second infectious disease program to Curative Biotech’s product development portfolio, which also includes a Metformin reformulation License from the National Eye Institute at the National Institutes of Health (NIH) to treat degenerative eye diseases and a novel monoclonal antibody/drug combination License from the National Cancer Institute at NIH to treat brain cancer.
The lack of a strong immune response to infections, including COVID-19, is a consequence of renal failure in general. This means that individuals with renal failure may receive a more severe form of COVID-19, increasing their chances of hospitalization or possibly death.Mid-Atlantic BioTherapeutics CEO Dr. David Horn added: “It is widely documented that kidney transplant recipients respond poorly to mRNA COVID-19 vaccinations. According to recent French statistics, even after four vaccination doses, many kidney transplant recipients had unsatisfactory outcomes.”